Peddock Capital Advisors LLC Cuts Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Peddock Capital Advisors LLC has reduced its stake in Gilead Sciences by 13%, holding 18,134 shares worth approximately $2,011,000 after selling 2,710 shares in the last quarter.
• Gilead Sciences reported $2.01 EPS for the quarter, exceeding analyst expectations, with revenues up 1.4% year-over-year, totaling $7.08 billion.
• The company will pay a quarterly dividend of $0.79 per share on September 29, with a current dividend yield of 2.8% and a payout ratio of 62.95%.

Peddock Capital Advisors LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,134 shares of the biopharmaceutical company's stock after selling 2,710 shares during the quarter. Peddock Capital Advisors LLC's holdings in Gilead Sciences were worth $2,011,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Ariel Investments LLC increased its holdings in Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock worth $48,229,000 after acquiring an additional 30,630 shares during the period. Golden State Wealth Management LLC raised its holdings in Gilead Sciences by 14.5% in the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after buying an additional 109 shares during the last quarter. Swedbank AB raised its holdings in shares of Gilead Sciences by 0.8% during the first quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company's stock valued at $237,393,000 after purchasing an additional 16,663 shares during the last quarter. Focus Partners Wealth boosted its position in shares of Gilead Sciences by 21.2% in the first quarter. Focus Partners Wealth now owns 142,666 shares of the biopharmaceutical company's stock worth $15,986,000 after purchasing an additional 24,930 shares during the period. Finally, Covea Finance boosted its position in shares of Gilead Sciences by 69.5% during the second quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company's stock worth $5,732,000 after acquiring an additional 21,200 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $114.40 on Wednesday. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The business's 50 day moving average is $114.21 and its two-hundred day moving average is $109.98. The company has a market cap of $141.95 billion, a P/E ratio of 22.79, a P/E/G ratio of 0.76 and a beta of 0.36. Gilead Sciences, Inc. has a 12 month low of $81.83 and a 12 month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's payout ratio is currently 62.95%.

Analyst Ratings Changes

GILD has been the subject of a number of recent analyst reports. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a research note on Friday, July 25th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a report on Tuesday, August 19th. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Dbs Bank upgraded Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Finally, UBS Group boosted their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $117.17.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider directly owned 113,193 shares in the company, valued at $12,855,329.01. This represents a 2.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 82,000 shares of company stock worth $9,390,030. Company insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.